These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20130423)

  • 1. EGFR signaling and drug discovery.
    Lurje G; Lenz HJ
    Oncology; 2009; 77(6):400-10. PubMed ID: 20130423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of growth factor signalling.
    Wakeling AE
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM; Allen GW; Bonner JA
    J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
    Cooper JB; Cohen EE
    Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Druggable signaling proteins.
    Sioud M; Leirdal M
    Methods Mol Biol; 2007; 361():1-24. PubMed ID: 17172705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB receptors and signaling pathways in cancer.
    Hynes NE; MacDonald G
    Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
    Papageorgio C; Perry MC
    Cancer Invest; 2007 Oct; 25(7):647-57. PubMed ID: 18027154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging strategies for ErbB ligand-based targeted therapy for cancer.
    Tsujioka H; Yotsumoto F; Shirota K; Horiuchi S; Yoshizato T; Kuroki M; Miyamoto S
    Anticancer Res; 2010 Aug; 30(8):3107-12. PubMed ID: 20871027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinases as targets in the treatment of solid tumors.
    Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
    Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family.
    Sartor CI
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):15-20; discussion 92-100. PubMed ID: 11236022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HER1/EGFR: a molecular approach to cancer therapy.
    Arteaga C
    Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel targets for anticancer treatment development in colorectal cancer.
    Macarulla T; Ramos FJ; Capdevila J; Saura C; Tabernero J
    Clin Colorectal Cancer; 2006 Nov; 6(4):265-72. PubMed ID: 17241511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting integrin beta4 for cancer and anti-angiogenic therapy.
    Giancotti FG
    Trends Pharmacol Sci; 2007 Oct; 28(10):506-11. PubMed ID: 17822782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.